Trial Profile
TALAPRO 1: A Phase 2, Open-Label, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2024
Price :
$35
*
At a glance
- Drugs Talazoparib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms Talapro-1
- Sponsors Pfizer
- 24 Oct 2023 Results (data cutoff date: 4 Sep 2020) of a biomarker analysis assessing ctDNA and its associations with antitumor activity presented at the 48th European Society for Medical Oncology Congress
- 08 May 2023 Status changed from active, no longer recruiting to completed.
- 06 May 2023 This trial has been completed in Germany, according to European Clinical Trials Database record.